Kiniksa Pharmaceuticals International (NASDAQ: KNSA) is scheduled to release its earnings report for the fourth quarter of 2025 on Tuesday, February 24, 2026, before the market opens. Analysts anticipate that the company will report earnings of $0.37 per share and revenue of $200.855 million for the quarter. The earnings call will take place at 8:30 AM ET, providing investors and stakeholders an opportunity to gain insights into the company’s financial performance and outlook.
Current Market Performance and Stock Activity
As of Friday, Kiniksa Pharmaceuticals’ stock opened at $47.77. The company has demonstrated significant growth, evident from its 50-day moving average of $42.72 and a 200-day moving average of $39.41. With a market capitalization of $3.62 billion, the stock’s price-to-earnings ratio stands at 106.16, while the beta value is 0.06. Over the past year, shares have ranged from a low of $18.25 to a high of $47.86.
Recent insider trading activity indicates some shifts in ownership. On February 12, Director Barry D. Quart sold 2,690 shares at an average price of $45.00, totaling $121,050. Following this transaction, Quart owns 12,546 shares, valued at approximately $564,570, reflecting a 17.66% decrease in his stake. Additionally, Chief Financial Officer Mark Ragosa sold 17,845 shares on February 9 at an average price of $43.28, amounting to $772,331.60. Ragosa now holds 12,086 shares, valued at around $523,082.08, marking a significant 59.62% reduction in his ownership.
Analyst Ratings and Market Sentiment
A range of brokerages has recently assessed Kiniksa Pharmaceuticals. On January 13, Zacks Research downgraded the company from a “hold” to a “strong sell” rating. Conversely, Canaccord Genuity Group initiated coverage with a “buy” rating and set a price objective of $62.00. The Goldman Sachs Group raised its price target from $45.00 to $55.00, maintaining a “buy” rating. Weiss Ratings reaffirmed a “hold (c)” rating, while Wedbush increased their target from $48.00 to $50.00, giving Kiniksa an “outperform” rating.
Currently, seven investment analysts rate the stock as a “Buy,” one analyst has issued a “Hold” rating, and another has given a “Sell” rating. According to MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of “Moderate Buy” with a target price of $53.71.
Kiniksa Pharmaceuticals International, founded in 2013 and headquartered in Lexington, Massachusetts, focuses on developing therapies for patients with life-threatening and debilitating immune-mediated diseases. The company emphasizes a patient-centric approach to create a diversified portfolio of marketed products and clinical-stage candidates. Its lead product is Ilaris (canakinumab), an interleukin-1β blocker used for various conditions, including systemic juvenile idiopathic arthritis and adult-onset Still’s disease.
As Kiniksa prepares for its upcoming earnings report, investors and analysts will closely monitor the company’s performance and strategic direction in the biopharmaceutical landscape.
